Shares of Resverlogix Corp. (TSE:RVX – Get Free Report) traded up 16.7% on Friday. The company traded as high as C$0.12 and last traded at C$0.10. Approximately 113,926 shares traded hands during mid-day trading, an increase of 246% from the average session volume of 32,944 shares. The stock had previously closed at C$0.09.
Resverlogix Stock Performance
The company’s 50 day moving average price is C$0.10 and its 200-day moving average price is C$0.10. The stock has a market cap of C$36.15 million, a P/E ratio of -2.62 and a beta of 0.12. The company has a debt-to-equity ratio of -82.47, a quick ratio of 0.04 and a current ratio of 0.04.
Resverlogix Company Profile
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
Read More
- Five stocks we like better than Resverlogix
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
